Covid-19 roundup: Fauci, Collins intervene to stop FDA plasma authorization, citing weak data; Roche, Regeneron try to take antibodies global
The FDA has placed on hold an emergency authorization for the use of plasma as a Covid-19 treatment following the intervention of top federal health officials who claimed the available data were too weak, according to a report in the New York Times.
NIAID clinical director H. Clifford Lane confirmed the hold to the Times, adding plasma may still be authorized sometime in the future.
Much has been made about the prospect of utilizing donated plasma from recovered Covid-19 patients to treat those currently infected with the disease. The theory goes that antibodies in the plasma can help reduce the time patients spend in hospitals as well as mortality rates if the treatment is administered quickly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
